Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
3.
Clin Infect Dis ; 45(5): 527-33, 2007 Sep 01.
Artigo em Inglês | MEDLINE | ID: mdl-17682984

RESUMO

BACKGROUND: In contrast to pharmaceutical manufacturers, compounding pharmacies adhere to different quality-control standards, which may increase the likelihood of undetected outbreaks. In 2005, the Centers for Disease Control and Prevention received reports of cases of Serratia marcescens bloodstream infection occurring in patients who underwent cardiac surgical procedures in Los Angeles, California, and in New Jersey. An investigation was initiated to determine whether there was a common underlying cause. METHODS: A matched case-control study was conducted in Los Angeles. Case record review and environmental testing were conducted in New Jersey. The Centers for Disease Control and Prevention performed a multistate case-finding investigation; isolates were compared using pulsed-field gel electrophoresis analysis. RESULTS: Nationally distributed magnesium sulfate solution (MgSO(4)) from compounding pharmacy X was the only significant risk factor for S. marcescens bloodstream infection (odds ratio, 6.4; 95% confidence interval, 1.1-38.3) among 6 Los Angeles case patients and 18 control subjects. Five New Jersey case patients received MgSO(4) from a single lot produced by compounding pharmacy X; culture of samples from open and unopened 50-mL bags in this lot yielded S. marcescens. Seven additional case patients from 3 different states were identified. Isolates from all 18 case patients and from samples of MgSO(4) demonstrated indistinguishable pulsed-field gel electrophoresis patterns. Compounding pharmacy X voluntarily recalled the product. Neither the pharmacy nor the US Food and Drug Administration could identify a source of contamination in their investigations of compounding pharmacy X. CONCLUSIONS: A multistate outbreak of S. marcescens bloodstream infection was linked to contaminated MgSO(4) distributed nationally by a compounding pharmacy. Health care personnel should take into account the different quality standards and regulation of compounded parenteral medications distributed in large quantities during investigations of outbreaks of bloodstream infection.


Assuntos
Bacteriemia/epidemiologia , Fármacos Cardiovasculares/efeitos adversos , Surtos de Doenças , Contaminação de Medicamentos , Sulfato de Magnésio/efeitos adversos , Infecções por Serratia/etiologia , Serratia marcescens/patogenicidade , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Bacteriemia/microbiologia , Procedimentos Cirúrgicos Cardíacos , Centers for Disease Control and Prevention, U.S./estatística & dados numéricos , Infecção Hospitalar/epidemiologia , Infecção Hospitalar/microbiologia , Composição de Medicamentos/efeitos adversos , Composição de Medicamentos/normas , Feminino , Humanos , Los Angeles/epidemiologia , Masculino , Pessoa de Meia-Idade , New Jersey/epidemiologia , Fatores de Risco , Infecções por Serratia/epidemiologia , Serratia marcescens/isolamento & purificação , Estados Unidos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA